Vectura narrows half year profits

27th Nov 2009 07:20

Respiratory inhaler firm Vectura reported a 67% reduction in half year pre-tax losses and said it plans to establish an infrastructure in the US market.Loss after tax reduced to £3.3m in the half year ended 30 September compared with £10.0m last time. Revenues increased by 71% to £22.8m. Vectura ended the half year with £76.3m of cash and cash equivalents. 'In the short-term we will continue to manage cash carefully and fund increased investment in our own proprietary development activities from both current revenue streams and cash resources,' said the group.'Vectura intends to establish an infrastructure in the lucrative US market. In the short term the activities will focus on product development and business development, with an ultimate aim of growing the US business in order to fully exploit the commercial value of our speciality products.